Icotinib And Rh-Endostatin As First Line Therapy In Advanced Non Small Cell Line Cancer Patients Harboring Activating Epidermal Growth Factor Receptor Mutations.
JOURNAL OF CLINICAL ONCOLOGY（2016）
Abstract
e20074Background: It is unclear about the clinical outcome of the combination of icotinib and rh-endostatin (Endostar) in treating advanced non-small cell lung cancer (NSCLC) patients harboring epi...
MoreTranslated text
Key words
epidermal growth factor receptor,epidermal growth factor,rh-endostatin
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined